ATE258946T1 - Verfahren zur herstellung von polyamidketten von genauer länge und deren konjugate mit proteinen - Google Patents

Verfahren zur herstellung von polyamidketten von genauer länge und deren konjugate mit proteinen

Info

Publication number
ATE258946T1
ATE258946T1 AT99943873T AT99943873T ATE258946T1 AT E258946 T1 ATE258946 T1 AT E258946T1 AT 99943873 T AT99943873 T AT 99943873T AT 99943873 T AT99943873 T AT 99943873T AT E258946 T1 ATE258946 T1 AT E258946T1
Authority
AT
Austria
Prior art keywords
chains
conjugates
proteins
precise length
producing polyamide
Prior art date
Application number
AT99943873T
Other languages
English (en)
Inventor
Keith Rose
Original Assignee
Gryphon Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gryphon Sciences filed Critical Gryphon Sciences
Application granted granted Critical
Publication of ATE258946T1 publication Critical patent/ATE258946T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/06Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
    • C08G73/10Polyimides; Polyester-imides; Polyamide-imides; Polyamide acids or similar polyimide precursors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/04Preparatory processes
    • C08G69/06Solid state polycondensation
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10Alpha-amino-carboxylic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Polyamides (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
AT99943873T 1998-08-28 1999-08-23 Verfahren zur herstellung von polyamidketten von genauer länge und deren konjugate mit proteinen ATE258946T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9835198P 1998-08-28 1998-08-28
US10526198P 1998-10-22 1998-10-22
US12426699P 1999-03-11 1999-03-11
PCT/US1999/019280 WO2000012587A2 (en) 1998-08-28 1999-08-23 Polyamide chains of precise length, methods to manufacture them and their conjugates

Publications (1)

Publication Number Publication Date
ATE258946T1 true ATE258946T1 (de) 2004-02-15

Family

ID=27378582

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99943873T ATE258946T1 (de) 1998-08-28 1999-08-23 Verfahren zur herstellung von polyamidketten von genauer länge und deren konjugate mit proteinen
AT03023018T ATE364654T1 (de) 1998-08-28 1999-08-23 Polyamideketten von genauer länge und deren konjugate mit proteinen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT03023018T ATE364654T1 (de) 1998-08-28 1999-08-23 Polyamideketten von genauer länge und deren konjugate mit proteinen

Country Status (13)

Country Link
US (2) US6552167B1 (de)
EP (1) EP1107998B1 (de)
JP (1) JP2002528562A (de)
KR (1) KR20010085742A (de)
CN (1) CN1330675A (de)
AT (2) ATE258946T1 (de)
AU (1) AU764144B2 (de)
CA (1) CA2351739A1 (de)
DE (3) DE69914611T2 (de)
DK (1) DK1400551T3 (de)
ES (1) ES2170042T3 (de)
HK (1) HK1043801A1 (de)
WO (1) WO2000012587A2 (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69914611T2 (de) * 1998-08-28 2004-12-23 Gryphon Therapeutics, Inc., South San Francisco Verfahren zur herstellung von polyamidketten von genauer länge und deren konjugate mit proteinen
DE19924606A1 (de) * 1999-05-28 2000-11-30 Graffinity Pharm Design Gmbh Ligand-Anker-Konjugate
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
JP2004507557A (ja) * 2000-09-01 2004-03-11 グリフォン セラピューティクス,インコーポレーテッド 求核物質に対して安定なチオエステル生成化合物、製造および使用の方法
AU2001273388B2 (en) * 2000-09-08 2005-01-13 Gryphon Therapeutics, Inc. "Pseudo"-native chemical ligation
US7118737B2 (en) * 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
JP4387669B2 (ja) 2000-10-13 2009-12-16 ザイジェン エス.アー. 新規なトランスポーターペプチド配列による生物学的エフェクターの細胞内送達
US7033597B2 (en) * 2000-10-13 2006-04-25 Université de Lausanne Intracellular delivery of biological effectors
US20040138412A1 (en) * 2001-09-07 2004-07-15 Paolo Botti Extended native chemical ligation
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
EP1616021A4 (de) * 2002-12-30 2006-08-30 Gryphon Therapeutics Inc Multiplex-polymerligation
AU2003303595A1 (en) 2002-12-30 2004-07-29 Gryphon Therapeutics, Inc. Water-soluble thioester and selenoester compounds and methods for making and using the same
US7084245B2 (en) 2003-05-12 2006-08-01 Affymax, Inc. Peptides that bind to the erythropoietin receptor
CA2525399A1 (en) 2003-05-12 2004-11-25 Affymax, Inc. Novel spacer moiety for poly(ethylene glycol)-modified peptide-based co mpounds
KR20060028675A (ko) * 2003-05-12 2006-03-31 아피맥스, 인크. 신규한 폴리 (에틸렌 글리콜) 개질 화합물 및 그의 용도
SI1625156T1 (sl) * 2003-05-12 2013-02-28 Affymax, Inc. Peptidi, ki se veĹľejo k eritropoetinskemu receptorju
CA2552043A1 (en) 2004-01-21 2005-08-04 Novo Nordisk A/S Transglutaminase mediated conjugation of peptides
NZ548256A (en) * 2004-02-02 2010-02-26 Ambrx Inc Modified human four helical bundle polypeptides and their uses
WO2006069220A2 (en) * 2004-12-22 2006-06-29 Ambrx, Inc. Modified human growth hormone
US7588745B2 (en) * 2004-04-13 2009-09-15 Si Options, Llc Silicon-containing products
US7632924B2 (en) * 2004-06-18 2009-12-15 Ambrx, Inc. Antigen-binding polypeptides and their uses
MX2007000728A (es) * 2004-07-21 2007-03-15 Ambrx Inc Polipeptidos biosinteticos que utilizan amino acidos no naturalmente codificados.
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
JP2008519858A (ja) * 2004-11-11 2008-06-12 アフィーマックス・インコーポレイテッド エリスロポエチンレセプターに結合する新規ペプチド
AU2005323106B2 (en) 2004-12-22 2010-07-29 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
AU2005319518B2 (en) 2004-12-22 2010-09-09 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
KR101224781B1 (ko) 2004-12-22 2013-01-21 암브룩스, 인코포레이티드 비천연적으로 코딩된 아미노산을 포함하는 인간 성장호르몬의 조제물
ES2435522T3 (es) 2005-02-02 2013-12-20 Novo Nordisk A/S Derivados de insulina
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US20100135959A1 (en) 2005-06-03 2010-06-03 Ambrx, Inc. Human Interferon Molecules and Their Uses
EP1937824B1 (de) 2005-08-18 2013-03-13 Ambrx, Inc. trna-zusammensetzungen und deren verwendungen
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007059312A2 (en) 2005-11-16 2007-05-24 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
ES2546282T3 (es) * 2006-02-14 2015-09-22 Novo Nordisk Health Care Ag Acoplamiento de polipéptidos en el extremo C-terminal
EP2035450A2 (de) 2006-05-26 2009-03-18 Amylin Pharmaceuticals, Inc. Zusammensetzung und verfahren zur behandlung von dekompensierter herzinsuffizienz
US8501693B2 (en) * 2006-08-04 2013-08-06 Amylin Pharmaceuticals, Llc Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen
EP2059527B1 (de) 2006-09-01 2014-12-03 Novo Nordisk Health Care AG Modifizierte glykoproteine
EP2061878B1 (de) 2006-09-08 2014-01-08 Ambrx, Inc. Hybridunterdrücker-trna für wirbeltierzellen
PT2064333E (pt) 2006-09-08 2014-06-09 Ambrx Inc Supressor híbrido arnt para células de vertebrados
CN106008699A (zh) * 2006-09-08 2016-10-12 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
WO2008067729A1 (fr) * 2006-12-06 2008-06-12 Nankai University Polypeptides et leur procédé de synthèse
CN103804489A (zh) 2006-12-15 2014-05-21 巴克斯特国际公司 具有延长的体内半衰期的因子VIIa-聚唾液酸结合物
HRP20120522T1 (hr) 2007-03-30 2012-08-31 Ambrx Modificirani fgf-21 polipeptidi i njihova uporaba
CN103965347B (zh) 2007-05-02 2017-07-18 Ambrx公司 经修饰干扰素β多肽和其用途
NZ603812A (en) 2007-11-20 2014-06-27 Ambrx Inc Modified insulin polypeptides and their uses
NZ602170A (en) 2008-02-08 2014-03-28 Ambrx Inc Modified leptin polypeptides and their uses
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
PT2318029T (pt) 2008-07-23 2018-01-10 Ambrx Inc Polipéptidos de g-csf bovino modificados e suas utilizações
MX2011003196A (es) 2008-09-26 2011-04-27 Ambrx Inc Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales.
DK2342223T3 (en) 2008-09-26 2017-07-24 Ambrx Inc Modified animal erythropoietin polypeptides and their uses
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
KR101759300B1 (ko) * 2009-07-27 2017-07-31 리폭센 테크놀로지즈 리미티드 비혈액 응고 단백질의 글리코폴리시알화
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
SG10201401194VA (en) 2009-07-27 2014-07-30 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
KR101912335B1 (ko) 2009-07-27 2018-10-26 리폭센 테크놀로지즈 리미티드 비혈액 응고 단백질의 글리코폴리시알화
US20120283171A1 (en) 2009-12-21 2012-11-08 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
EP2516455A4 (de) 2009-12-21 2013-05-22 Ambrx Inc Modifizierte schweine-somatotropin-polypeptide und deren verwendungen
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
PH12013500241A1 (en) 2010-08-17 2013-03-11 Ambrx Inc Modified relaxin polypeptides and their uses
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
WO2012048721A1 (en) 2010-10-14 2012-04-19 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
PL2654794T3 (pl) 2010-12-22 2020-07-27 Baxalta GmbH Materiały i sposoby sprzęgania rozpuszczalnej w wodzie pochodnej kwasu tłuszczowego z białkiem
US8440309B2 (en) 2011-01-31 2013-05-14 Confluent Surgical, Inc. Crosslinked polymers with the crosslinker as therapeutic for sustained release
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
HUE043552T2 (hu) 2012-06-08 2019-09-30 Sutro Biopharma Inc Antitestek, amelyek tartalmaznak helyspecifikus nem természetes aminosav maradékokat, eljárások elõállításukra és eljárások használatukra
EP2863955B1 (de) 2012-06-26 2016-11-23 Sutro Biopharma, Inc. Modifizierte fc-proteine mit nichtnatürlichen ortsspezifische aminosäureresten, konjugate daraus, verfahren zu deren herstellung und verfahren zu deren verwendung
US9682934B2 (en) 2012-08-31 2017-06-20 Sutro Biopharma, Inc. Modified amino acids
WO2014068463A2 (en) * 2012-11-03 2014-05-08 Mahesh Kandula Compositions and methods for the treatment of inflammation and metabolic disorders
AU2014301631A1 (en) 2013-06-26 2015-08-27 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
SMT202100388T1 (it) 2014-10-24 2021-09-14 Bristol Myers Squibb Co Polipeptidi fgf-21 modificati e loro usi
US11806371B2 (en) 2017-01-19 2023-11-07 The University Of Chicago Oxalobacter formigenes (Of)-derived factors for the treatment of treatment/prevention of excess oxalate levels
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
EP3625247A4 (de) 2017-05-16 2021-03-24 The University of Chicago Zusammensetzungen und verfahren zur behandlung und/oder vorbeugung von pathogenen pilzinfektionen und zur aufrechterhaltung von mikrobiomkommensalismus
EP3836949A4 (de) 2018-07-18 2022-03-09 The University of Chicago Zusammensetzungen mit sel1-abgeleiteten peptiden und verfahren zur behandlung/prävention von zu hohen oxalatspiegeln und damit einhergehenden erkrankungen
EP3849614B1 (de) 2018-09-11 2023-12-20 Ambrx, Inc. Interleukin-2-polypeptidkonjugate und deren verwendungen
JP2022512746A (ja) 2018-10-19 2022-02-07 アンブルックス,インコーポレイテッド インターロイキン-10ポリペプチド複合体、その二量体、およびそれらの使用
CA3128081A1 (en) 2019-02-12 2020-08-20 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
CN110256668B (zh) * 2019-06-04 2021-12-10 中国科学技术大学 高分子量呋喃基芳香聚酰胺及其制备方法和应用
IL296099A (en) 2020-03-11 2022-11-01 Ambrx Inc Interleukin-2 polypeptide conjugates and methods of using them
US20230302150A1 (en) 2020-08-20 2023-09-28 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
CA3213805A1 (en) 2021-04-03 2022-10-06 Feng Tian Anti-her2 antibody-drug conjugates and uses thereof
WO2026043823A2 (en) 2024-08-19 2026-02-26 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of preparation and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE343210B (de) 1967-12-20 1972-03-06 Pharmacia Ab
US4028315A (en) * 1970-10-16 1977-06-07 E. R. Squibb & Sons, Inc. Solid phase synthesis of peptides
GB1479268A (en) 1973-07-05 1977-07-13 Beecham Group Ltd Pharmaceutical compositions
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE2360794C2 (de) 1973-12-06 1984-12-06 Hoechst Ag, 6230 Frankfurt Verfahren zur Herstellung von Peptiden
US4028313A (en) * 1975-06-25 1977-06-07 Bayer Aktiengesellschaft Process for the production of water-dispersible polyhydroxyl compounds
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
GB1578348A (en) 1976-08-17 1980-11-05 Pharmacia Ab Products and a method for the therapeutic suppression of reaginic antibodies responsible for common allergic
US4192798A (en) * 1978-11-20 1980-03-11 Bioresearch, Inc. Rapid, large scale, automatable high pressure peptide synthesis
JPS5792435A (en) 1980-11-28 1982-06-09 Matsushita Electric Ind Co Ltd Formation of magnetic tape
US4415665A (en) 1980-12-12 1983-11-15 Pharmacia Fine Chemicals Ab Method of covalently binding biologically active organic substances to polymeric substances
US4414147A (en) 1981-04-17 1983-11-08 Massachusetts Institute Of Technology Methods of decreasing the hydrophobicity of fibroblast and other interferons
JPS57206622A (en) 1981-06-10 1982-12-18 Ajinomoto Co Inc Blood substitute
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
IL74177A (en) 1984-02-03 1989-09-10 Abbott Lab Stabilized enzyme conjugate composition containing a calcium salt and a polyethylene glycol
US4732863A (en) 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US4824659A (en) * 1985-06-07 1989-04-25 Immunomedics, Inc. Antibody conjugates
IT1190389B (it) * 1985-09-19 1988-02-16 Eniricerche Spa Esapeptidi ad attivita' ipotensiva
US4802512A (en) 1986-02-25 1989-02-07 Kabushiki, Kaisha, Kodera, Denshi, Seisakusho Automatic wire decorticating and cutting method and apparatus
US4745180A (en) 1986-06-27 1988-05-17 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using heparin fragments
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5097070A (en) * 1989-11-03 1992-03-17 Texaco Chemical Company High molecular weight trifunctional polyoxyethylene amines
WO1993020236A1 (en) 1992-04-03 1993-10-14 Applied Biosystems, Inc. Probe composition and method
IL107715A0 (en) * 1992-11-25 1994-02-27 Baxter Int Water soluble non-immunogenic polyamide cross-linking agents
FR2698628B1 (fr) * 1992-12-02 1995-02-17 Fournier Ind & Sante Analogues de 15-déoxyspergualine, leur procédé de préparation et leur utilisation en thérapeutique.
NZ250375A (en) 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
JP3351476B2 (ja) 1993-01-22 2002-11-25 三菱化学株式会社 リン脂質誘導体及びそれを含有するリポソーム
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
AU1444095A (en) * 1993-12-27 1995-07-17 Baxter International Inc. Water soluble non-immunogenic polyamide cross-linking agents
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
NZ322686A (en) 1995-10-19 2000-01-28 Univ Washington Discrete-length polyethene glycols
DE69914611T2 (de) * 1998-08-28 2004-12-23 Gryphon Therapeutics, Inc., South San Francisco Verfahren zur herstellung von polyamidketten von genauer länge und deren konjugate mit proteinen

Also Published As

Publication number Publication date
EP1107998A2 (de) 2001-06-20
AU764144B2 (en) 2003-08-14
KR20010085742A (ko) 2001-09-07
HK1043801A1 (zh) 2002-09-27
DE69936322D1 (de) 2007-07-26
ES2170042T3 (es) 2004-10-01
CN1330675A (zh) 2002-01-09
DE69914611D1 (de) 2004-03-11
AU5688399A (en) 2000-03-21
ATE364654T1 (de) 2007-07-15
US6552167B1 (en) 2003-04-22
DE69936322T2 (de) 2008-02-21
DK1400551T3 (da) 2007-10-15
JP2002528562A (ja) 2002-09-03
CA2351739A1 (en) 2000-03-09
ES2170042T1 (es) 2002-08-01
EP1107998B1 (de) 2004-02-04
WO2000012587A2 (en) 2000-03-09
US20030228274A1 (en) 2003-12-11
DE69914611T2 (de) 2004-12-23
WO2000012587A8 (en) 2001-09-20
WO2000012587A3 (en) 2000-06-02
DE1107998T1 (de) 2002-10-17

Similar Documents

Publication Publication Date Title
ATE258946T1 (de) Verfahren zur herstellung von polyamidketten von genauer länge und deren konjugate mit proteinen
DE69831402D1 (de) Nicht antigen wirkende verzweigte polymerkonjugate
CA2174325A1 (en) Non-antigenic branched polymer conjugates
DE69633669D1 (de) Verfahren zur zelltransfektion mit liposomal-verkapselten nukleinsäuren
NO975729D0 (no) Forbindelser og peptider som binder til etytropoietinreseptoren
CY1109480T1 (el) ΠΡΩΤΕΪΝΕΣ ΣΥΝΔΕΣΗΣ Gag
DE69028412D1 (de) Verfahren zum transport von molekülen in eukaryotenzellen
DE68903482D1 (de) Zement, verfahren zur herstellung dieses zements und verfahren zur herstellung von produkten mit diesem zement.
HK1049283A1 (zh) 兩性聚合物及含其的多肽共軛物
CY1112101T1 (el) Νευροτροφικοι παραγοντες
DE69033705D1 (de) Hybride immunglobuline
ATE265488T1 (de) Kombinationen zur einführung von nucleinsäuren in zellen
DK113790A (da) Vandig gel paa basis af hyaluronsyre og desoxyribonucleinsyre anvendelig i kosmetik og fremgangsmaade til fremstilling deraf
ES2120964T3 (es) Peptidos osteogenicos.
SE8804164D0 (sv) Farmaceutisk beredning
DE60018564D1 (de) Funktionsfähige poly-alpha-aminosäurederivate zur modifizierung von biologisch wirksamen stoffen und deren herstellung
ATE527358T1 (de) Ribosomen inaktivierendes protein vom typ-1
DE59703693D1 (de) Pflanzenbehandlungsmittel
ES549185A0 (es) Procedimiento para sintetizar peptidos a partir de aminoaci-dos
DE69806164D1 (de) Verfahren zur herstellung von polyanilin mit hohem molekulargewicht in seiner emeraldinform
ATE481641T1 (de) Verfahren zur fixierung eines proteins auf einem pyrrolpolymerisat, und dessen verwendung zur herstellung eines sensors
ATA7997A (de) Verfahren zur herstellung von chitosan-ethylendiamintetraacetat konjugaten
EP1414299A4 (de) Im wesentlichen homogenes, biologisch beeinflussendes material mit einem vorbestimmten verhältnis von biologisch beeinflussender komponente zu zell-targeting-komponente, verfahren zur herstellung eines solchen materials und anwendungsverfahren dafür
ATE248807T1 (de) Verfahren zur herstellung von n-hydrocarbyl- substituierten amiden
DE59106997D1 (de) Ancrod ähnliche proteine, ihre herstellung und verwendung.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties